As a matter of fact, "On December 20, 2021, Novavax, Inc. (the “Company”) issued a press release announcing that the European Commission (the “EC”) granted the Company conditional marketing authorization for its Nuvaxovid™ COVID-19 Vaccine."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.